Introduction
Cancer of the prostate is the most frequent malignant tumor in men and is a leading cause of cancer-related death in men over age 50 (Mettlin 1993; Moul, 1996) . Autopsy studies have revealed that, although localized carcinomas exist in most elderly males, the majority of these were asymptomatic and medically unimportant (Whittemore et al., 1991) . These localized lesions can be cured by surgical or radiological interventions. Unfortunately, once prostate cancer spreads beyond its capsular localization, current therapies only extend life by about a year, even in patients with minimal metastatic disease (Shultz, 1996) . In order to design rational therapies aimed at limiting prostate cancer progression we must ®rst de®ne key operative molecules in the various steps of this progression cascade.
Prostate cancer develops from epithelial cells that escape the growth and dierentiation control of the prostate microenvironment. These cells acquire properties that enable them to penetrate surrounding basement membranes, invade local tissue and grow independently of the prostate environment as metastases. Tumor invasion is a distinct property of tumor progression as is evident by the ability of a variety of agents to block invasiveness in vitro. For example, the tumor suppressor KAI blocks motility and invasion but not growth of colon cancer cells (Takaoka et al., 1998) , and the calcium channel inhibitor CAI prevents transmigration of Matrigel even in tumor cell lines in which proliferation is unaected (Jacobs et al., 1997) . Interestingly, estrogen can increase tumor growth even while suppressing invasiveness (Rochefort et al., 1998) . On the other hand, transforming growth factor-b (TGFb), which usually is anti-proliferative, can enhance tumor progression, possibly via its motility promoting eects (Barrack, 1997) . Finally, the distinction between invasion and growth has been clearly demonstrated by an in vivo xenograft model of human prostate carcinoma in which disruption of PLCg signaling prevents tumor invasiveness but not tumor growth (Turner et al., 1996 (Turner et al., , 1997 .
Overexpression of EGF receptors in DU145 human prostate carcinoma cells promotes EGF receptordependent invasiveness both in vitro (Xie et al., 1995) and in vivo (Turner et al., 1996) . Chen et al. (1994b) have demonstrated that EGF receptor-mediated motility requires PLCg signaling by using a signalingrestricted EGF receptor construct or pharmacological agents to block lipase activity of PLCg. In the absence of PLCg activity, haptokinetic motility is unaected (Chen et al., 1994b; Ware et al., 1998) , and mitogenesis is actually increased by the lack of a competing cell response . Similar results have shown that PLCg is required for motility but not mitogenic signaling from receptors for platelet-derived growth factor (PDGF) (Bornfeldt et al., 1995; Kundra et al., 1994a) and insulin-like growth factor (IGF-1) (Wennstrom et al., 1994) . Lastly, targeting PLCg signaling in mouse xenografts, utilizing either pharmacological (U73122) or molecular (dominant-negative PLCz fragment of PLCg-1) agents, abrogates EGF mediated invasiveness (Turner et al., 1996 (Turner et al., , 1997 . Thus, PLCg and subsequent downstream signaling events may represent targets for dysregulated cell motility as opposed to mitogenesis.
One area drawing increasing attention is that of altered transcription pro®les in motility and invasion. Whether these are due to genetic alterations or epigenetic responses to extracellular signals requires further investigation. There appears to be a 4 ± 8 h induction period for EGF-induced motility that may re¯ect the need for altered transcription (Maheshwari et al., 1999) . This requirement for de novo transcription has been further implicated by the sensitivity of motility to transcription inhibitors (Bauer et al., 1992; Chen et al., 1994a; Gordon and Staley, 1990) . Interestingly, urokinase-type plasminogen activator binding to its receptor and signaling via the ERK MAP kinases for only 30 min can stimulate mammary carcinoma cell motility as measured over 24 h, suggesting a persistent change in the cell's transcription program (Nguyen et al., 1998) . A few reports have pointed to the fos family of transcription factors as the mediator of growth factor promoted motility and invasion (Kustikova et al., 1998; Malliri et al., 1998) . In sum, there are solid indications that cell motility requires altered transcription of select mRNA species and although a few invasion genes have been described using a candidate gene approach, the roster of speci®c elements involved in invasion remains incomplete.
To expand our understanding of the events controlling EGF mediated motility, and thus of PLCg signaling, we have employed cDNA microarrays to compare the transcriptional pro®les of 4608 genes in DU145 cells that express EGF receptors with dierential competency for activation of PLCg. Our data illustrate the power of syngeneic cells combined with high-throughput genomics in identifying candidate prostate invasiveness genes. A novel PLCg-regulated gene, DPM3/prostin-1, is presented as a new invasion suppressor.
Results

Identification of putative invasion promoter and suppressor genes
We have examined the expression pro®les of 4608 randomly selected genes in three DU145 prostate carcinoma cell sublines that vary in their invasive potential because of dierential competence for PLCg signaling. We approached this using high-density cDNA microarrays to analyse the transcriptional alterations coincident with onset of the invasive phenotype. Our arrays displayed 4608 randomly selected, minimally redundant cDNAs in duplicate (Heller et al., 1997; Karpf et al., 1999; Schena et al., 1995 Schena et al., , 1996 . Figure 1a shows a schematic diagram of the cell line comparisons. In experiment A, we compared the transcriptional pro®les of parental DU145 cells with DU145 cells stably overexpressing full length epidermal growth factor receptor (c'1186 EGFR). In experiment B we compared parental DU145 cells with DU145 cells stably overexpressing a truncated epidermal growth factor receptor incapable of activating PLCg (c'973 EGFR) (Xie et al., 1995) . These sublines vary in their invasive capacity where c'1186 EGFR4parental DU1454c'973 EGFR (Turner et al., 1996 (Turner et al., , 1997 . Figure 1b shows a portion of an array from experiment A, parental DU145 versus c'1186 EGFR, and is typical of the array quality that we obtained. A detailed evaluation of the arrays was achieved by plotting the ratio of the hybridization signals (red signal/green signal) for each of the 4608 genes in the comparison. This analysis revealed that most genes failed to respond to introduction of the full length EGFR and de®ned a control versus experimental ratio of 1.0+0.172 (mean+s.d.) For the entire gene set. Expression ratios for individual points lying outside the standard deviation for the entire gene set identi®ed candidate, dierentially regulated genes. A similar analysis was performed for experiment B, parental DU145 versus c'973 EGFR expressing cells. Ratios from each comparison were then ranked from the most positive change to the most negative change and those values lying at least two standard deviations from the mean expression ratio were categorized according to their regulation in c'1186 EGFR expressing cells versus their regulation in c'973 EGFR expressing cells.
The changes we saw fell into three classes: (i) changes that were parallel in c'1186 EGFR and c'973 EGFR expressing cells; (ii) changes that were unique to c'1186 EGFR or c'973 EGFR expressing cells; and (iii) changes that were opposite in c'1186 EGFR and c'973 EGFR expressing cells. The majority of changes (8.5% of total) were shared between cells expressing c'1186 EGFR and cells expressing c'973 EGFR. This indicated that only a minority of the genes regulated by the EGF receptor requires an intact PLCg pathway. This simpli®ed the interpretation of our array data and demonstrated the strength of this model system in identifying those genes directly involved in the PLCg pathway and, therefore, in the control of EGFR mediated invasion. The second and third categories of changes contained a much smaller set of genes that represent candidate invasion regulators. We were most interested in the third class of genes, those that showed opposite regulation in experiment A versus experiment B. We found only 11 genes (0.23% of total) that conform to the criterion of having opposite expression in c'1186 EGFR versus c'973 EGFR expressing cells as compared to the parental DU145 cells (Table 1) . These were classi®ed as putative invasion promoters, if they were highest in c'1186 EGFR cells, or suppressors, if they were highest in c'973 EGFR cells. Ratios of the red/green signals for each array element were calculated, averaged between the duplicate points and plotted against the array element number (each individual gene). As expected, most genes remain unchanged with a mean ratio of 1. 0+0.172 (mean+s.d.) . Points lying at least two standard deviations above or below the mean expression ratio were selected for comparison to those from experiment B cells and suppressed in c'1186 EGFR expressing cells. In addition, introduction of a dominant-negative fragment of PLCg causes complete abrogation of invasiveness in c'1186 EGFR expressing cells (Turner et al., 1997) . Prostin-1 was highly expressed in these cells. These results con®rmed the microarray data and demonstrated that prostin-1 is regulated by PLCg signaling.
Prostin-1 corresponded to EST sequence AA047755 and was a member of the unigene cluster Hs.110477. This unigene cluster contained 41 additional EST sequences that were overlapping and assembled into two distinct contiguous sequences. The ®rst contiguous sequence resulted in a clone of 525 base pairs that contained a short open reading frame predicting a protein of 122 amino acids (molecular weight 13 275 Da). The second contig resulted in a clone of 374 bp that also contained an open reading frame. In this case, the predicted protein contained 92 amino acids with a molecular weight of 10 092 Da. The two sequences appear to dier through splicing of a 5 prime exon that could result in a long and a short form of the protein (Figure 3) . The shorter open reading frame is entirely contained within the longer contig in that the sequences of each contig were indentical from base pair position 19 in the short form through the poly(A) + tail. Each contig contained a consensus polyadenylation signal. Based on the mRNA size for prostin-1 as seen in our Northern analysis (Figure 2 ), we concluded that we have obtained the full-length sequence for prostin-1 electronically. We obtained several of the clones (GenomeSystems, Inc.) and sequenced them to con®rm our informatics-based analysis. 
Prostin-1 is a novel gene product
The putative proteins encoded by prostin-1 were novel sequences and, therefore, required additional analyses to form a hypothesis about their function. Using BLAST (Altschul et al., 1990 (Altschul et al., , 1997 and other protein motif searches, we found homologs of prostin-1 in mouse, rat, C. elegans, Drosophila and yeast databases, indicating that prostin-1 is an evolutionarily conserved protein (Figure 4a ). The highest degree of conservation within this new protein family occurs within the Cterminal region. The N-terminal region is predicted to contain a membrane-spanning region while the Cterminus is predicted to reside in the cytoplasm. We were unable to ®nd sequences other than human that encoded the long form of prostin-1 and, therefore, concluded that the short form is more typical. Homology searches of prostin-1 against known proteins revealed an interesting relationship to several cytoskeletal proteins, typi®ed by plexins. The 27 residues at the C-terminus of prostin-1 showed substantial homology (80%) with a domain of undescribed function contained in murine plexins, membrane proteins involved in neuronal cell contact, axon guidance and fasciculation (Kameyama et al., 1996; Winberg et al., 1998) . This same domain was also shared with cytoskeletal keratin, non-muscle myosin heavy chain and paramyosin, all known cytoskeletal proteins (Figure 4b ). Given the importance of cytoskeletal rearrangement for cell motility (Lauenburger and Horwitz, 1996; Stossel, 1993; Wells et al., 1998) and thus in the development of invasiveness and metastasis, our identi®cation of prostin-1 as a novel candidate invasion suppressor illustrates the potential of microarray analyses to de®ne new molecular determinants that accompany tumor progression to invasiveness. While this manuscript was in preparation, Maeda et al. (2000) disclosed the sequence of DPM3, a subunit of dolichol-phosphate-mannose synthase. The short form of prostin-1 is identical to the sequence of DPM3. While this initial identi®cation provides for possible functional roles, the exact role of DPM3/ prostin-1 in the synthase complex appears to be as an adapter or stabilizer, and not one of enzymatic function (Maeda et al., 2000) . Thus, it remains to be determined whether this short peptide might also function in other cellular machineries.
DPM3/prostin-1 is expressed ubiquitously and is androgen responsive
We next examined the distribution of DPM3/prostin-1 within human tissues. Northern analyses revealed the expression of DPM3/prostin-1 in nearly all of the 16 normal tissues examined (Figure 5a) . Similarly, seven of eight tumor cell lines examined demonstrated DPM3/prostin-1 gene expression (Figure 5b ). Only Molt-4 cells lacked expression of DPM3/prostin-1.
In order to ascertain the situation for dierential DPM3/prostin-1 expression, we next performed a virtual Northern using the Serial Analysis of Gene Expression Tag to Gene Mapping database curated by the NCBI (Lal et al., 1999; Velculescu et al., 1995; Zhang et al., 1997) . At the time of analysis, the database oered 2 902 360 SAGE tags derived from 69 libraries representing diverse human tissue types. SAGE tags for DPM3/prostin-1 were found in 49 of the 69 libraries available. The highest number of DPM3/prostin-1 tags (345 tags/million) was seen in the ovarian cancer cell library, OVCA432-2. Next to this library, DPM3/prostin-1 tags were most abundant in libraries derived from the prostate cancer cell line LNCaP after treatment with androgen analogues (Figure 6a ). In one case, tags corresponding to DPM3/prostin-1 increased nearly 10-fold after androgen treatment with R1881. In a second case, higher levels of DPM3/prostin-1 tags were observed in LNCaP cells treated with dihydrotestosterone (DHT). The SAGE database contained only one set of libraries derived from de novo normal prostate and prostate cancer. In this set, the prostate tumors were noninvasive and showed higher numbers of DPM3/prostin-1 tags than that seen in normal tissue (59 tags/million in the normal versus 130 tags/million in the tumor).
We then performed Northern analysis on RNA from LNCaP cells treated with DHT (Figure 6b) . A The predicted open reading frame of human DPM3/prostin-1 was aligned with putative homologs from mouse, rat, C. elegans and yeast using the Clustal method in DNASTAR. Identical residues are shaded. Conservation among the species is highest at the C-terminus with the N-terminus showing conserved hydrophobic, putative membrane spanning regions. (b) A BLAST search against all known proteins revealed that the 27 amino acids at the C-terminus of DPM3/prostin-1 share close homology with several cytoskeletal proteins. Shown in the alignment are murine plexins 1 and 2, human cytoskeletal keratin and human nonmuscle myosin heavy chain (NMMHC). Identical or conserved residues between DPM3/prostin-1 and aligned proteins are in bold signi®cant increase in DPM3/prostin-1 expression was seen at 12 and 24 h after treatment with DHT, verifying the results from the SAGE analysis.
High level expression of DPM3/prostin-1 leads to apoptosis
Our analysis of DPM3/prostin-1 suggested it as a transmembrane protein with some homology to known cytoskeletal proteins. To begin an analysis of the functional role of DPM3/prostin-1 in invasion we next examined the subcellular distribution of DPM3/ prostin-1 when overexpressed in Cos-1 cells. DPM3/ prostin-1 was tagged with a FLAG epitope and transfected into Cos-1 cells. Following 48 h of incubation cells were ®xed and stained with anti-FLAG speci®c antibodies. Examination of cells expressing DPM3/prostin-1 at 48 h after transfection revealed a high rate of cell death. Based on visual inspection, 71.5% (98/137) of cells expressing DPM3/prostin-1 displayed the apoptotic feature of condensed nuclei as compared to 4.9% (6/122) of cells expressing bovine alkaline phosphatase as a control. Cells expressing DPM3/prostin-1 underwent apoptosis and detached from the culture plate, obscuring clear assessment of subcellular distribution. To overcome this, we examined the distribution of DPM3/prostin-1 in cells prior to the onset of apoptosis. Figure 7a demonstrates the morphology and subcellular distribution of DPM3/ prostin-1 in Cos-1 cells at 24 and 48 h post-transfection. DPM3/prostin-1 expressing cells showed signs of apoptosis but at early time points revealed intense perinuclear localization of DPM3/prostin-1. This staining pattern is consistent with localization of DPM3/prostin-1 in the endoplasmic reticulum and con®rms observations presented by Maeda et al. (2000) . Closer inspection revealed ®lamentous staining + RNA was isolated and analysed by Northern blot using PCR-ampli®ed probes. Hybridization signals were quanti®ed using a phosphorimager, normalized to GAPDH, and displayed as relative phosphorescence units for FLAG-tagged DPM3/prostin-1 at sites distinct from the perinuclear staining. This raises the possibility that DPM3/prostin-1 functions at other locations.
Discussion
The power of any analysis is dictated by the model system investigated. Our previous work has determined that growth factor-induced cell motility promotes prostate cancer progression. We have identi®ed PLCg signaling as a critical intracellular pathway that promotes invasion (Glading et al., 2000) . These ®ndings were obtained using a panel of sublines of the human prostate carcinoma-derived line DU145 that have dierent invasive potentials. These sublines were generated by expressing exogenously-encoded EGFR in cells that already presented a TGFa-EGFR autocrine stimulatory loop (Xie et al., 1995) . Such an autocrine EGFR-stimulating loop is present in prostate carcinomas (Kim et al., 1999) . The two EGFR constructs (c'1186 and c'973) both activate the ERK MAP kinase (Chen et al., 1994b) and STAT pathways (David et al., 1996) but dier in that the c'1186 EGFR but not c'973 EGFR triggers the PLCg pathway (Chen et al., 1994a) . This dierential restriction of a single de®ned pathway was instrumental in narrowing the focus and possible candidates from pleuripotential signalers like EGFR.
One daunting problem with microarray analyses is that the large amount of data that one might generate requires substantial downstream investigation. Our data show that array analyses of syngeneic cell lines that isolate a particular signaling intermediary allow ®ltering of genes unrelated to the PLCg pathway and the invasive nature of these cells. If we just examine genes that were found to be altered in a two-way comparison of either c'1186 EGFR or c'973 EGFR expressing cells against parental DU145, we would have identi®ed approximately 8% of the genes as being altered by EGFR signaling. However, by presenting a hierarchical three-way comparison and limiting the signaling variable to a downstream event, PLCg activation, we were able to produce a manageable set of putative genes (*0.2% of examined genes). Further supporting the validity of this approach, genes surviving our analyses and ®lters included several with known promoter roles in tumor invasion. These included hepatocyte growth factor, insulin-like growth factor-1 (Boros and Miller, 1995) , platelet-derived growth factor (Kundra et al., 1994a,b) and the urokinase receptor (Andreasen et al., 1997; Reuning et al., 1998; Schmitt et al., 1995) . Each of these molecules has been implicated previously in tumor cell invasion and metastasis. The regulation of these genes by PLCg, however, is a novel observation.
Although our array analysis revealed a number of genes with interesting potential functions in invasion, we focused on the characterization of a novel gene that showed the most convincing negative association with invasiveness. DPM3/prostin-1 appears to be encoded by two messenger RNAs that are generated by dierential exon splicing. These splice variants would produce two distinct products that dier with respect to the length of their N-terminus. Based on two pieces of evidence, we believe the shorter form of DPM3/ prostin-1 is expressed in most tissues. First, our Northern analyses failed to detect two message sizes in the tissues we have examined. The message size we have detected is consistent with the shorter transcript. Second, our search for DPM3/prostin-1 homologs demonstrated that rat, mouse, C. elegans and S. pombe genomes all contain a DPM3/prostin-1 gene. In no case other than in human did we ®nd a homolog that corresponded to the long form of DPM3/prostin-1. Nevertheless, the long form of the DPM3/prostin-1 message is present in a number of clones from the dbEST database indicating that it is expressed. Further studies will be required to determine under what conditions and in which tumor types the long form of the DPM3/prostin-1 transcript is produced and Figure 7 Overexpression of DPM3/prostin-1 induces apoptosis in Cos-1 cells. (a) Cos-1 cells were transiently transfected with (left panels) FLAG-tagged DPM3/prostin-1 or (right panels) FLAG-tagged bovine alkaline phosphatase. At 24 h (upper panels) and 48 h (lower panels) following transfection, cells were ®xed and stained with anti-FLAG antibody. Primary antibody was detected using a FITC-conjugated secondary antibody and visualized using¯uorescence microscopy. At both 24 and 48 h post-transfection, BAP containing cells showed cytoplasmic staining and normal morphology. In contrast, DPM3/prostin-1 expressing cells showed signs of detachment at 24 h and condensed nuclei at 48 h. (b) Cos-1 cells transfected with FLAG-tagged DPM3/prostin-1 showed a ®lamentous staining distinct from cytoplasmic BAP seen in (a). Superimposition of DPM3/prostin-1 staining with the nuclear stain DAPI is shown in the right panel whether the translation start site produces the corresponding protein.
We found that the 92 amino acid peptide predicted for DPM3/prostin-1 was of novel sequence with some C-terminal homology to certain cytoskeletal proteins, typi®ed by plexins. This small size of DPM3/prostin-1 suggested a role as a regulator rather than an enzyme. This was con®rmed by Maeda et al. (2000) in that they recently puri®ed DPM3/prostin-1 as a component of the dolichol-phosphate-mannose synthase complex. They demonstrated that DPM3/prostin-1 lacked direct enzymatic activity but rather stabilized the activity of DPM1 and DPM2 (Maeda et al., 2000) . Interestingly, the domain in DPM3/prostin-1 that we found related to plexins and other cytoskeletal proteins was required for binding of DPM3 to the DPM synthase complex (Maeda et al., 2000) . DPM3 localized to the endoplasmic reticulum in human cells (Maeda et al., 2000) . This localization was con®rmed by our studies with DPM3/prostin-1 in Cos-1 cells, however, we observed expression of DPM3/prostin-1 in sites distinct from the ER. It is, therefore, possible that DPM3/ prostin-1 also functions in other protein complexes.
We found that DPM3/prostin-1 expression negatively associated with DU145 cell invasiveness, that PLCg signaling controlled its expression, and that androgen could induce its expression in non-invasive cell types. Each of these observations is consistent with a role of DPM3/prostin-1 and, perhaps the DPM synthase complex, in maintaining a non-invasive state. One hypothesis emerging from the studies of Maeda et al. (2000) suggests a role for the DPM synthase in establishing levels of GPI-linked cell surface receptors. This oers an intriguing possibility for the role of DPM3/prostin-1 in invasiveness. Under normal physiological conditions, it is possible that DPM3/prostin-1 helps maintain the levels of GPI-linked cell surface proteins, thus contributing to the maintenance of cell surface interactions with the extracellular matrix. In addition, overexpression of DPM3/prostin-1 caused detachment and apoptosis in Cos-1 cells while high levels of a control protein did not. This result may be due to disruption of cell surface interactions due to the high levels of DPM3/prostin-1 protein. Further studies are required to determine whether DPM3/prostin-1 has a true pro-apoptotic role in vivo as well as to pursue the functional roles of DPM3/prostin-1 in invasion. Our studies, however, demonstrate that an unbiased genomic approach, like microarray analysis, oers new hypotheses regarding the involvement of novel signaling pathways in biology and disease.
Dysregulated signaling through PLCg does not promote the entire transition from a normal cell to metastatic carcinoma. Rather this is likely but one key signal in one step of tumor progression. However, it is necessary to narrow these types of open-ended searches to enable one to study the resultant data points in depth, rather than selecting previously implicated genes from among a large pool of known and unknown candidates. This is especially likely to occur and be misleading when evaluating downstream signals from pleiotropic eectors, such as the EGF receptor and similar receptors. Our identi®cation of DPM3/prostin-1 as a novel, candidate invasion suppressor illustrates the potential of microarray analyses in de®ning new molecular determinants that accompany tumor progression to invasiveness. Continued application of microarray expression technology to this problem oers the promise of expanding our list of candidate invasiveness genes and, therefore, our list of therapeutic targets.
Materials and methods
Cell culture DU145 cells were propagated by standard methods (DMEM/ F12 media supplemented with 7.5% FCS) in the presence of selection agents (1 mg/ml G418 for c'1186 and c'973 DU145 plus 1.2 mg/ml methotrexate for PLCz-DU145 cells) Turner et al., 1997) . Cells were passaged in media/ FBS in the absence of selection agents for 3 days prior to testing. LNCaP cells were grown in RPMI-1640 supplemented with 10% fetal bovine serum, 1.0 mM sodium pyruvate, 2.0 mM L-glutamine, 50 units/ml penicillin G sodium and 50 mg/ml streptomycin sulfate. Cells were grown at 378C under 5% CO 2 . Media and supplements were obtained from Life Technologies, Inc.
Microarray experiments
Microarray slides were prepared as previously described (Heller et al., 1997; Karpf et al., 1999; Schena et al., 1995 Schena et al., , 1996 . Total RNA was prepared from each experimental condition using Trizol reagent (Life Technologies, Inc.) according to the manufacturer's instructions. Poly(A) + RNA was puri®ed from total RNA using the Oligotex-dT mRNA batch kit from Qiagen. Labeling and hybridization were performed as previously described (Heller et al., 1997; Karpf et al., 1999; Schena et al., 1995 Schena et al., , 1996 . Brie¯y, ®rst-strand cDNA probes were generated by incorporation of Cy3-dCTP or Cy5-dCTP (Amersham Pharmacia) during reverse transcription of 1 mg puri®ed mRNA. The resulting cDNA probes were puri®ed by vacuum ®ltration, denatured at 948C and hybridized to an arrayed slide overnight at 428C. Slides were washed in 16SSC/0.2% SDS for 10 min, then in 0.16SSC/0.2% SDS for 20 min. Slides were rinsed, dried and uorescence was captured using the Avalanche dual laser confocal scanner (Molecular Dynamics). Fluorescent intensities were quanti®ed using Arrayvision 4.0 (Imaging Research).
Northern analyses
Multiple human tissue mRNA blots purchased from Clontech were prehybridized at 658C for 1 h in Rapid-Hyb buer (Amersham Pharmacia), then hybridized with randomprimed, a-32 P-dCTP-labeled probe for 4 ± 16 h at 658C. Unbound probe was removed by washing twice in 26SSC/ 0.1% SDS at room temperature, then twice in 0.56SSC/ 0.1% SDS at 658C. Blots were exposed to a phosphor screen and scanned using a Phosphorimager (Molecular Dynamics).
LNCaP cells were plated at 10 6 cells/dish in 100 mm dishes and allowed to adhere overnight. The next day, media was replaced with RPMI-1640 with 10% charcoal-stripped serum and grown for 24 h. Cells were then treated with vehicle or 10 nM dihydrotestosterone (Sigma) for various time points. Total RNA was isolated using Trizol (Life Technologies, Inc.) and poly(A) + mRNA was selected using Oligotex (Qiagen). Two micrograms of poly(A) + mRNA was run on a denaturing formaldehyde agarose gel. RNA was transferred to nylon membrane (Amersham Pharmacia) and cross-linked. Blots were prehybridized at 428C for 1 h in UltraHyb buer (Ambion), then hybridized with random-primed, a-32 P-dCTPlabeled probe for overnight at 428C. Unbound probe was removed by washing twice in 26SSC/0.1% SDS at 428C, then twice in 0.16SSC/0.1% SDS at 428C. Blots were exposed to a phosphor screen and scanned using a Phosphorimager (Molecular Dynamics).
Cell transfections and immunostaining
DPM3/prostin-1 was cloned into pFLAG-CMV-2 (Kodak) for expression in Cos-1 cells. Transient transfections were performed using FuGene6 (Roche) according to manufacturer's protocol. Brie¯y, cells were seeded into 4-well chamber slides (Nunc) and allowed to adhere overnight. FuGene6 was diluted into serum-free media (Opti-Mem, Life Technologies, Inc.) and incubated at room temperature for 5 min. Plasmid (200 ng) was then added to FuGene and allowed to incubate for 15 min. Transfection mix was added directly to cells and incubated at 378C in 5% CO 2 for 24 ± 48 h. Cells were washed three times with TBS/Ca (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM CaCl 2 ), then ®xed with acetone/ methanol (1 : 1). After washing four more times with TBS/ Ca, slides were incubated with 10 mg/ml anti-FLAG M2 monoclonal antibody for 1 h. Slides were washed ®ve times with TBS/Ca and then incubated with 10 mg/ml goat-antimouse secondary antibody conjugated to Alexa 488 (Molecular Probes, Inc.) for 1 h in the dark. Slides were washed four times with TBS/Ca, mounted with a coverslip using ProLong Antifade kit (Molecular Probes, Inc.), and observed using a¯uorescence microscope.
